ANTI-HER2 BSAB KN026
HER2-positive Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltdmonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
1 Active assets in the HER2-positive Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
kn046 Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 | B |
Nivolumab Bolt Biotherapeutics, Inc. | Phase 1/2 | CC |
Trastuzumab Imbotolimod Bolt Biotherapeutics, Inc. | Phase 1/2 | CC |
vrn101099 Voronoi, Inc | Phase 1 | CC |
Epirubicin Carisma Therapeutics Inc | Phase 1 | CC |
Cyclophosphamide Carisma Therapeutics Inc | Phase 1 | CC |
ct-0508 Carisma Therapeutics Inc | Phase 1 | CC |
Pembrolizumab Carisma Therapeutics Inc | Phase 1 | CC |
Same molecule, other indications
ANTI-HER2 BSAB KN026 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →